Kornimate/medical-research-clean huggingface dataset:
hepatic mitochondrial function in youth

Conditions: Hepatic Steatosis; Bariatric Surgery Candidate; Adolescent Obesity; Obesity

Summary: assess the impact of bariatric surgery on hepatic energy metabolism and glucose and insulin dynamics in obese youth

a metabolic study that will be performed prior to and 12 months following bariatric surgery. the study will include 31-phosphorus magnetic resonance spectroscopy to measure phosphate concentrations in the liver; a 4 hour mixed meal tolerance test, an intravenous arginine test, abdominal magnetic resonance imaging (mri) for visceral and hepatic fat, magnetic resonance (mr) elastography of the liver, indirect calorimetry, body composition assessment with bodpod, serum metabolomics and hepatic tissue mitochondrial measures from the time of surgery only.

Eligibility criteria:
inclusion criteria: 1. obese youth ages 13-20 years, scheduled for bariatric surgery at children's hospital colorado 2. bmi 35-55 m2/kg 3. maximal body circumference \<200 cm exclusion criteria: 1. use of medications known to affect insulin sensitivity: oral glucocorticoids within 10; days, atypical antipsychotics, immunosuppressant agents, hiv medications. 2. infectious hepatitis 3. alcohol abuse 4. mitochondrial disease 5. type 2 diabetes 6. medications that affect hepatic outcomes (e.g. ppar-γ or ppar-α, metformin) 7. currently pregnant or breastfeeding women. development of pregnancy during the study period will necessitate withdrawal from the study. 8. severe illness requiring hospitalization within 60 days 9. diabetes, defined as hemoglobin a1c \> 6.4% 10. anemia, defined as hemoglobin \< 10 mg/dl 11. diagnosed major psychiatric or developmental disorder limiting informed consent 12. implanted metal devices that are not compatible with mri

Keywords: bariatric surgery hepatic mitochondria insulin secretion
rehabilitation glasses for the treatment of hemispatial neglect

Conditions: Hemispatial Neglect

Summary: this project is designed to test a lightweight, portable, computerized pair of glasses that will help reduce some of the cognitive deficits seen in patients who have suffered damage to their right cerebral hemisphere.

hemispatial neglect is the inability or failure to attend and respond to the left side of space. patients suffering right cerebral hemispheric damage from stroke or traumatic brain injury frequently suffer neglect and will ignore all information located in the left side of space. currently there is no effective rehabilitation technique to treat neglect and many of these patients have severe long-term disability. the goal of this project is to determine whether a prototypical pair of rehabilitation glasses can reduce the symptoms of hemispatial neglect.

Eligibility criteria:
inclusion criteria: * presence of hemispatial neglect as defined by behavioral inattention test score of 129 or worse (maximum score 146). exclusion criteria: * presence of aphasia at time of testing, * recent seizures * major psychiatric illness * prior unrelated neurological disease
evaluation of the efficacy and safety of treatments for patients hospitalized for covid-19 infection without signs of acute respiratory failure, in tunisia

Conditions: COVID 19; Patients Hospitalized

Summary: evaluation of the efficacy and safety of treatments for patients hospitalized for covid-19 infection without signs of acute respiratory failure, in tunisia multicentric randomized comparative study

arm 1: * hydroxychloroquine (hcq): 600 mg on the 1st day as a starting dose then 200 mg \* 2 /d for 9 days * azithromycin: 500 mg (1st day) then 250 mg / d for 4 days * usual standard treatment arm 2: * hcq: 600 mg on the 1st day as a starting dose then 200 mg \* 2 / d for 9 days * azithromycin: 500 mg (1st day) then 250 mg / d for 4 days * zinc: 220 mg per day for 10 days * usual standard treatment arm 3: * azithromycin: 500 mg (1st day) then 250 mg / d for 4 days * doxycycline: 200 mg per day for 10 days. * usual standard treatment

Eligibility criteria:
inclusion criteria: * confirmed patient covid19 positive with clinical signs of acute lower respiratory infection with signs of pneumonia or bronchitis: fever and / or cough and / or difficulty breathing in the absence of acute respiratory failure (pao2\> 60 mmhg) with plus or less : * chills * asthenia, fatigability * headache * arthromas myalgia * dry throat * rhinorrhea * an anosmia * chest pain * diarrhea * nausea and vomiting * absence of rhythm disturbance (qt interval \<500ms) * patients hospitalized in the medical service * 18 years old \<age \<80 years old * having given written consent for their participation in the study exclusion criteria: * allergy to macrolides, local anesthetics such as lidocaine or amide type and betalactamines * take hydroxychloquine in the previous month * severe / severe liver failure * kidney failure (gfr \<30 ml / min / 1.73 m2) * ongoing treatments with colchicine, ergot, rye, pimozide, mizolastine, simvastatin, lomitapide, alfuzosin, dapoxetine, avanafil, ivabradine, eplerenone, dronedarone, quetiapine, ticagrelor, cisapride, astemizole, terfenadine, ranolazine, domperidone. * complete branch block * hypovolemia * retinopathy including vitreous involvement * psoriasis * pregnant or breastfeeding woman * hypersensitivity to chloroquine or hydroxychloroquine or to any of the other ingredients of this medication
reconstruction of the bile duct with the round ligament

Conditions: Bile Duct Obstruction, Extrahepatic

Summary: the investigators developed a new surgical technique in order to reconstruct the bile duct with the round ligament

classically, the bile duct defect after bile duct injury or resection is achieved by bilioenteric reconstruction. however bilioenteric anastomosis is associated with long term complications including intrahepatic bile ducts infection, specific complications related to the roux en y jejunal loop and eliminate the endoscopic access to intrahepatic bile ducts. the investigators had recently developed a new surgical technique to reconstruct the veins with the parietal peritoneum with excellent results. accordingly the investigators decided to develop a new surgical technique in order to reconstruct the bile duct defects with the vascularized round ligament.

Eligibility criteria:
inclusion criteria: 1. radiological or operative diagnosis of bile duct injury or defect 2. can underwent surgical procedure exclusion criteria: 1) the absence of the round ligament

Keywords: bile duct injury bile duct defect round ligament reconstruction
cladribine dose escalation in conditioning regimen prior to allo-hsct for refractory acute leukemia and myelodysplastic syndromes

Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute

Summary: the investigators focused on patients with refractory acute leukemia or mds and designed a phase 1 trial of escalated cladribine doses in the cla-flu-bu rtc regimen using pk-guided myeloablative busulfan doses. this scheme allows combining different optimization of rtc experienced over years (flu-bu rtc, pk-guided myeloablative busulfan doses, a second purine analog cladribine) to approach a specific platform to treat refractory diseases.


Eligibility criteria:
inclusion criteria: * age 18-70 * ecog 0 or 1 * acute leukemia (aml or all) without criteria for cr or high risk mds without criteria for cr * availability of a donor among following ohla identical sibling ohaploidentical donor o10/10 or 9/10 allele-level hla matched unrelated donor * signed informed consent * patient affiliated to the national "social security" regimen or beneficiary of this regimen exclusion criteria: * contraindication for allo-hsct * cord blood allo-hsct * current active disease or positive serology for hiv, and/or hcv with detectable viremia and/ or hbv with positive hbs antigen. * renal failure with creatinine clearance \< 30 ml/ min * decompensated haemolytic anaemia * hypersensitivity to an active substance or to any of the excipients * acute urinary infection * pre-existing haemorrhagic cystitis * woman of childbearing potential not using an effective contraception . * pregnant or lactating women * any serious concurrent uncontrolled medical disorder * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Keywords: refractory acute leukemia refractory myelodysplastic syndrome cladribine dose escalation
open-label comparison of 24hr gastric ph on days 1, 2, 7 with once-daily administration of lavoltidine 40 mg.

Conditions: Gastroesophageal Reflux Disease; Reflux, Gastroesophageal

Summary: current treatment for gastroesophageal reflux disease(gerd)confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric acid suppression. clinical data on lavoltidine demonstrates a rapid onset of action, high potency, and prolonged duration of effect after single dose. since tolerance to the class of compounds to which lavoltidine belongs may be dose dependent, the current study is designed to determine if 40mg lavoltdine given for 7days develops tolerance.


Eligibility criteria:
inclusion criteria: * healthy male, from 18-55 years * have bmi from 19-30 kg/m2 * do not present with abnormal clinical lab findings * are able to tolerate a nasogastric ph electrode. exclusion criteria: * helicobacter-positive on a c13 urea breath test * have a baseline median 24-hour gastric ph\>3

Keywords: pharmacodynamics, tolerance h2 antagonist, ah23844, lavoltidine, gastroesophageal reflux disease (gerd), pharmacokinetics,
open-label extension study of dccr in pws followed by double-blind, placebo-controlled, randomized withdrawal period

Conditions: Prader-Willi Syndrome

Summary: this is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating the safety and efficacy of dccr treatment.

115 pws participants who completed clinical study c601 will be enrolled into the ole period. all participants in the open label extension (ole) period will receive open-label dccr. the actual number of participants eligible to enroll in the double-blind, placebo-controlled, randomized withdrawal (rw) period will be limited to those participants taking dccr in the ole period at the time of the rw period visit 1 (baseline/randomization visit).the treatment groups in the c602 rw period are those participants randomized to receive dccr and those participants randomized to receive placebo. participants will be randomized in a 1:1 ratio (dccr:placebo).

Eligibility criteria:
ole period key inclusion criteria: * successful completion of clinical study c601 * provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (subjects, as appropriate) ole period key exclusion criteria: * positive urine pregnancy test (in females of child-bearing potential) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 90 days after study participation * any new disease, condition, or circumstance which would prevent, in the opinion of the investigator, the patient from completing all study visits and assessments required by the protocol (e.g., an anticipated change of care setting) rw period key inclusion criteria: * provide voluntary, written informed consent (parent\[s\] / legal guardian\[s\] of participant); provide voluntary, written assent (participants, as appropriate); this includes consent for randomization and potential treatment with placebo for up to 16 weeks * currently participating in clinical study c602 and complete the ole end of treatment visit procedures rw period key exclusion criteria: * positive urine pregnancy test (in females of child-bearing potential) * females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation

Keywords: pws prader-willi syndrome
combination chemotherapy +/- radiation in high risk hodgkin's disease

Conditions: Hodgkin Disease

Summary: patients with 3 or more adverse prognostic factors have a higher relapse rate. significant anti-tumor activity in hodgkin's lymphoma has been reported with two new drugs:gemcitabine and vinorelbine. the introduction of these new agents with their different mechanisms of action into the stanford v regimen may increase effectiveness while maintaining a favorable toxicity profile with respect to fertility and a low risk of secondary leukemia. on this basis, we propose a new regimen, stanford vi, for patients with bulky and advanced hd with 3 or more risk factors.

patients will receive chemotherapy weekly for 19 weeks, alone or followed by irradiation as indicated per protocol guidelines. * doxorubicin 25 mg/m2 iv w 1,3,5,7,9,11 * vinblastine 6 mg/m2 iv w 1,3,5,7,9,11 * cyclophosphamide 750 mg/m2 iv w 1, 5, 9 * etoposide2 60 mg/mg2 x 2 iv w 3, 7,11 * vincristine1 1.4 mg/m2 iv w 2,4,6,8,10,12 (cap @ 2mg) * bleomycin 5 u/m2 iv w 2,4,6,8,10,12 * gemcitabine 1250 mg/m2 iv w 13,15,17,19 * vinorelbine 25 mg/m2 iv w 13,15,17,19 * prednisone 40 mg/m2 po qod w 1-10, taper

Eligibility criteria:
inclusion criteria: * untreated, locally extensive or advanced stage classical hodgkin's disease * 3 or more adverse risk factors * age \> 18 years and \< 70 years. * no prior invasive malignancies for \> 5 years except curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. * ecog performance status 0 to 2 * wbc \> 4000/µl * platelets \> 100,000/µl * creatinine \< 2.0mg/dl * bilirubin \< 5.0mg/dl exclusion criteria: * hiv-positive * pregnant or currently breast feeding women * lymphocyte predominant hodgkin's disease

Keywords: nodular sclerosis lymphocyte rich lymphocyte depleted mixed cellularity
crossover study to assess the safety and pharmacokinetic of pegylated somatropin(peg somatropin) in ghd children

Conditions: Growth Hormone Deficiency

Summary: the purpose of the phase 1 study is to assess the safety and pharmacokinetics of peg somatropin, which administered once per week, compared with the daily used somatropin, and to evaluate the safety and possibility to replace daily used somatropin.


Eligibility criteria:
inclusion criteria: * have a height less than two standard deviations (sd) below the median height for individuals of the same age or height, a growth velocity (gv) ≤4 cm/yr, a gh peak concentration \ 3 years;have a height value recorded 3 months before the start of gh treatment to calculate pre-treatment gv; receive no prior gh treatment or stop the gh treatment for more than 4 weeks;sign informed consent exclusion criteria: * patients with liver and kidney dysfunction (alt\> upper limit of normal 2 times, cr\> upper limit of normal), hepatitis b virus detection, antigen-hbc, hbsag and hbeag are positive * patients with known to a highly allergic constitution or allergic to the drug of this study * patients with diabetes, serious cardiopulmonary, blood system, malignant tumor and other diseases or systemic infection in immunocompromised and mental diseases * patients with other growth disorders, such as turner syndrome, constitutional delay of growth and puberty, laron syndrome, gh receptor deficiency, girls with growth delay have not ruled out chromosomal abnormalities * participated in clinical trials of other drugs in 3 months * other cases that the researchers considered unsuitable for this clinical trial

Keywords: pegylated somatropin peg-gh phase 1 study pharmacokinetics
hospital ederly life program for surgical patients

Conditions: To Investigate the Mortality of the Frailty Patients

Summary: frailty is the clinically recognizable medical condition, also called syndrome or phenotype, that is, the result of processes leading to an increased vulnerability for serious deteriorations in health and the diminished ability to cope with physical stressors. recently, frailty has emerged as a significant risk factor for adverse postoperative outcomes. it is related to declines in energy, strength, and function as well as to an increased inflammatory state, including elevated levels of interleukin 6 (il-6), c-reactive protein (crp), and anelevated white blood cell count . frailty, as defined frailty, as defined in the landmark paper by fried, included at least three of five of the following criteria: unintentional loss of weight, low physical activity, low energy, low grip strength, and a slowed walking speed. since then, various frailty scoring lists have been designed to optimize the predictive value. one of these is the edmonton frail scale (efs), an instrument that can be assessed quickly, using only a simple questionnaire which usually does not require more than five minutes to be completed and which covers most domains of functioning, making it easy and fast to get a reliable impression of the degree of frailty.the aim of this study was to determine which factors,with emphasis on frailty, significantly influence postoperative outcome after elective noncardiac surgery as measured by the comprehensive complication index (cci).


Eligibility criteria:
inclusion criteria: * elective noncardiac surgery exclusion criteria: * patients who don't cooperate
prenatal aspirin and postpartum vascular function

Conditions: Preeclampsia; Microvascular Function

Summary: preeclampsia is a pregnancy disorder affecting \~5-10% of pregnancies in the united states. women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. the reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. low dose aspirin (lda; 75-150mg/daily) is currently the most effective and clinically accepted therapy for reducing preeclampsia prevalence in women at high risk for developing the syndrome. the purpose of this study is to interrogate the mechanisms by which lda therapy mitigates persistent vascular dysfunction in postpartum women who have had preeclampsia. in this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a dime-sized area of the skin in women who have had a history of preeclampsia. as a compliment to these measurements, they also draw blood from the subjects and isolate the inflammatory cells.


Eligibility criteria:
inclusion: * 18 years or older, * 12 weeks to 5 years postpartum * and one of the following: 1. women who had a normal pregnancy and did not use low does aspirin (lda) during pregnancy, 2. women who had a normal pregnancy and used lda during pregnancy, 3. women who had preeclampsia and did not use lda during pregnancy, 4. women who had preeclampsia and used lda during pregnancy. exclusion: * current daily aspirin use, * skin diseases, * current tobacco use, * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (ckd) defined as reduced egfr \< 60 ml/min/1.73m2, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of hypertension prior to pregnancy, * history of gestational diabetes, * current pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs.
dental anaesthesia affects pain level

Conditions: Dental Anxiety; Anesthesia, Local

Summary: background: needles are the most feared tools, making anaesthetic injection a worrying practice. aim: to compare intraosseous (ioa) and needle-free dental anaesthesia (nfa) methods that painless anaesthesia. design: twenty patients aged 8-10 years were included in this cross-over study. to determine the anxiety levels and pain experienced by the patients, visual and behavior scales were used. the pulse rate (pr) and opiorphin levels (ol) determined. the friedman and wilcoxon signed-rank tests were used. p\<0.05 was considered significant.


Eligibility criteria:
inclusion criteria: * patients aged 8-10 years, * systemically healthy, * had undergone dental treatment (except for extraction) previously but with at least 1 week passed since then * were compatible enough to undergo therapy in the clinic in a sitting position, * had infection between the roots with a rate over 1/3, had 2/3 root formation, * had been indicated for extraction of the maxillary primary molar teeth (55/65 no. teeth), * did not have acute and/or subacute infection of the related or other teeth or mouth and surrounding tissues exclusion criteria: * who scored above 41 in the state anxiety subscale and above 44 in the trait anxiety subscale of the spielberger state-trait anxiety scale (ssas-saas) * not meeting the inclusion criteria
treatment duration on normobaric hyperoxia in acute ischemic stroke

Conditions: Stroke, Acute; Neuroprotection; Endovascular Treatment

Summary: normoxia hyperoxia (nbo) is a neuroprotective approach that can be implemented early. nbo is simple and non-invasive and can be used at home or in an ambulance to ensure the shortest possible time after cerebral ischemia occurs. the previous study by the investigators suggested that nbo therapy in the early stage of cerebral ischemia has a neuroprotective effect on ischemic brain injury. although the neuroprotective effect of nbo has been demonstrated, the optimal duration of treatment for nbo to exert neuroprotective effect is still unclear. therefore, further discussion of the duration of nbo treatment will contribute to the clinical application of nbo and provide a definite theoretical basis for the treatment of cerebral infarction.


Eligibility criteria:
inclusion criteria: * symptoms and signs were consistent with acute anterior circulation stroke, * nihss score≥6分;alberta stroke program early ct score (aspects)≥6; * met the indications for endovascular therapy; * (level of consciousness)nihss score 0 or 1; mrs score was 0-1 before stroke * the time from onset to randomization was within 24 hours; * preoperative cta or mra confirmed the presence of large vessel occlusion (internal carotid artery or middle cerebral artery m1, m2 segments); * patients and their families signed informed consent exclusion criteria: * rapid neurological function improvement, nihss score less than 10 points, or evidence of vessel recanalization prior to randomization; * seizures at stroke onset; * intracranial hemorrhage; * symptoms suggestive of subarachnoid hemorrhage, even if ct scan was normal; * known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with inr \> 3.0 or ptt \> 3 times normal; * platelet count of less than 100,000 per cubic millimeter; * severe hepatic or renal dysfunction; * severe, sustained hypertension (systolic blood pressure \>185 mmhg or diastolic blood pressure \>110 mmhg) * baseline blood glucose of \ 400mg/dl (22.20 mmol) active and chronic obstructive pulmonary disease or acute respiratory distress syndrome; * \>3 l/min oxygen required to maintain peripheral arterial oxygen saturation (sao2) 95% as per current stroke management guidelines; * medically unstable; * life expectancy\<90 days; * patients who could not complete the 90-day follow-up; * evidence of intracranial tumor; * patients with anemia or polycythemia vera or other situations that require urgent oxygen inhalation; * patients with upper gastrointestinal bleeding or nausea or vomiting so that they cannot cooperate with the mask to inhale oxygen. * a history of severe allergies to contrast agents;